New Diabetes Treatment 2020

Asweetlife is taking a look at the new diabetes tech that you can look forward to in 2020.
New diabetes treatment 2020. If theres a theme of the upcoming year that theme is interoperability. Humalog insulin lispro 3. New treatment could help diabetes patients achieve remission written by ginger vieira on november 12 2018 new procedure encourages cell growth and spurs the pancreas to produce insulin once again. The 2020 standards of medical care in diabetes includes all of adas current clinical practice recommendations and is intended to provide clinicians patients researchers payers and others with the components of diabetes care general treatment goals and tools to evaluate the quality of care.
The various makers of insulin pumps continuous glucose monitors and insulin management algorithms have all been very busy making agreements with each other so that tech from one company can talk to tech from another. Most type 2 diabetes drugs work by helping your body make insulin or use it better. Lantus insulin glargine 5. Your kidneys try to keep glucose a kind of sugar your cells use for energy out of your pee.
New research from the icahn school of medicine at mount sinai in new york has found that treatment with a combination of two different types of drugs can help restore insulin production in people. This algorithm for the comprehensive management of persons with type 2 diabetes t2d was developed to provide clinicians with a practical guide that considers the whole patient his or her spectrum of risks and complications and evidence based approaches to treatment. 2020 may also bring a new tandem mini pump dubbed tsport it will be a hybrid of sorts roughly half the size of the tslim x2 pump and without any display screen at all. Gvoke glucagon injection is a ready to use room temperature stable liquid glucagon for the treatment of severe hypoglycemia in diabetes patients ages 2 years and older.
It is now clear that the progressive pancreatic beta cell. The recommendations are based on an extensive review of the clinical diabetes literature supplemented with input from ada staff and the medical community at large. Bydureon exenatide originally approved in 2012 astrazenecas bydureon exenatide extended release was the very first once weekly.